RE: RE: RE: biOasis study favours trastuzumab-TranExcellent point about Genentech pmrider. With patent for Herceptin expiring soon, Genentech should view this as an excellent opportunity to keep their share of the pie. If they were to recombine Herceptin with p97, they wouldn't have to worry about generics taking a huge chunk out of genentech's profits.
it will be interesting to see how this pans out.
TB